Evercore ISI cuts Clorox stock price target on margin pressures

Analysts turned more cautious on Clorox after its Q3 fiscal 2026 results and reduced full-year guidance to $5.45-$5.65 from $5.95-$6.30. Evercore ISI cut its price target to $110 from $115 and kept an Underperform rating, while Goldman Sachs lowered its target to $83 from $94 and maintained Sell. Q3 adjusted EPS of $1.64 beat consensus by $0.10, but management flagged ERP and GOJO-related distortions, weaker U.S. organic sales, and fourth-quarter gross margin pressure of 41%-42% versus the Street's 46%.

Analysis

The key second-order issue is that Clorox is entering a period where reported results will become less informative precisely when the market wants cleaner proof of stabilization. ERP disruption plus the GOJO integration create a classic “visibility gap,” which usually compresses the multiple before it improves fundamentals because investors pay less for earnings they cannot underwrite. That makes the stock vulnerable to a low-quality rally on any near-term EPS beat, since the market will likely fade numbers that are increasingly driven by timing, cost deferrals, and accounting noise rather than true demand inflection.

The more important read-through is not just margin pressure, but the imbalance between volume elasticity and cost pass-through. If U.S. organic sales are already lagging scanner data, it implies the category may be holding up better than Clorox’s share, which is a warning sign that promotional intensity or private-label share gains are taking hold. In that setting, higher resin costs are not merely a margin headwind; they can force either price increases that further pressure volume or margin sacrifice that undermines EPS credibility into FY27.

The market may be underestimating how often “temporary” guidance cuts become structural when implemented on top of systems changes and acquisitions. For the next 1-2 quarters, the stock likely trades more on trust than on fundamentals: any execution misstep can drive another de-rating, while a clean print could still fail to rerate the shares because the Street will demand evidence after the distortion period ends. That argues for treating upside as tactical rather than durable until post-ERP comparables emerge.

The contrarian angle is that the selloff may already be discounting a lot of the near-term damage, especially if the shares are near multi-year lows and valuation is now leaning on a fair-value anchor. But the rebound case requires not just stabilization in EPS, it requires proof that share losses are contained without incremental promo spend. Until that happens, downside risk is more asymmetric over the next 3-6 months than upside is over the next 12 months.

Key Decisions for Investors

• Short CLX on strength into any post-earnings bounce; use a 1-3 month horizon because the next several prints will still be dominated by ERP/GOJO noise and margin uncertainty. Risk/reward favors fading rallies rather than pressing after fresh lows.
• Structure a bearish call spread in CLX 1-2 quarters out to monetize elevated uncertainty while capping premium outlay; best if implied vol remains bid on guidance risk. This is preferable to outright puts if you want defined theta and event-risk exposure.
• Pair trade: long a higher-quality defensive staple with cleaner execution visibility vs short CLX for the next 3-6 months. The relative trade is aimed at multiple dispersion, not category demand, and should work if the market continues to penalize opaque earnings.
• Avoid adding on valuation alone until there is at least one quarter of post-distortion evidence showing stable U.S. share and no further guide-downs. The risk is that the current “cheap” multiple becomes a value trap if the FY27 reset is still incomplete.
• For catalyst traders, consider covering shorts only if management proves gross margin can hold above Street expectations despite resin pressure; otherwise the stock likely remains range-bound to lower. A clean margin print would be the first credible signal that the de-rating has run its course.